(Q55060237)

16 June 2018

title

Guselkumab: First Global Approval. (English)

1 reference

16 June 2018

0 references

Anthony Markham

1

1 reference

16 June 2018

publication date

1 September 2017

1 reference

16 June 2018

published in

Drugs

1 reference

16 June 2018

volume

77

1 reference

16 June 2018

issue

13

1 reference

16 June 2018

page(s)

1487-1492

1 reference

16 June 2018

https://scigraph.springernature.com/pub.10.1007/s40265-017-0800-7

exact match

0 references

cites work

Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0800-7

First-in-human study to assess guselkumab (anti-IL-23 mAb) pharmacokinetics/safety in healthy subjects and patients with moderate-to-severe psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0800-7

Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: Results of the randomized, double-blind, Phase 3 NAVIGATE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0800-7

Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0800-7

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active compa

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0800-7

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-bl

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0800-7

A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0800-7

10.1007/S40265-017-0800-7

21 January 2018

Identifiers

DOI

1 reference

16 June 2018

Dimensions Publication ID

1091235188

0 references

1 reference

16 June 2018